These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20156150)

  • 1. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients.
    Huang F; Fu Y
    Curr Clin Pharmacol; 2010 May; 5(2):115-24. PubMed ID: 20156150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.
    Hing JP; Piotrovsky V; Kimko H; Brashear HR; Zhao Q
    Curr Med Res Opin; 2005 Apr; 21(4):483-8. PubMed ID: 15899095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
    Seltzer B
    Clin Interv Aging; 2010 Feb; 5():1-6. PubMed ID: 20169037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations.
    Piotrovsky V; Van Peer A; Van Osselaer N; Armstrong M; Aerssens J
    J Clin Pharmacol; 2003 May; 43(5):514-23. PubMed ID: 12751272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.
    Yao C; Raoufinia A; Gold M; Nye JS; Ramael S; Padmanabhan M; Walschap Y; Verhaeghe T; Zhao Q
    J Clin Pharmacol; 2005 May; 45(5):519-28. PubMed ID: 15831775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.
    Monbaliu J; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2003; 53(7):486-95. PubMed ID: 12918214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine extended release.
    Robinson DM; Plosker GL
    CNS Drugs; 2006; 20(8):673-81; discussion 682-3. PubMed ID: 16863272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
    Lilienfeld S
    CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat.
    van Beijsterveldt L; Geerts R; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2004; 54(2):85-94. PubMed ID: 15038457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of galantamine.
    Farlow MR
    Clin Pharmacokinet; 2003; 42(15):1383-92. PubMed ID: 14674789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.
    Wilkinson D; Murray J
    Int J Geriatr Psychiatry; 2001 Sep; 16(9):852-7. PubMed ID: 11571763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine: a review of its use in Alzheimer's disease.
    Scott LJ; Goa KL
    Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
    Dunbar F; Zhu Y; Brashear HR
    Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Galantamine, an acetylcholinesterase inhibitor with various actions].
    Allgaier C; Arendt T
    Med Monatsschr Pharm; 2004 Jul; 27(7):223-7. PubMed ID: 15296356
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic rationale for switching from donepezil to galantamine.
    Maelicke A
    Clin Ther; 2001; 23 Suppl A():A8-12. PubMed ID: 11396871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine hydrobromide: an agent for Alzheimer's disease.
    Zarotsky V; Sramek JJ; Cutler NR
    Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.